Bulletin
Investor Alert

Personalis Inc.

NAS: PSNL

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 13, 2021, 5:44 p.m.

/zigman2/quotes/212754973/composite

$

18.15

Change

0.00 0.00%

Volume

Volume 5,773

Quotes are delayed by 20 min

/zigman2/quotes/212754973/composite

Today's close

$ 18.57

$ 18.15

Change

-0.42 -2.26%

Day low

Day high

$17.30

$19.16

Open

52 week low

52 week high

$10.02

$53.46

Open

Company Description

Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Alt...

Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.

Valuation

Price to Sales Ratio

18.20

Price to Book Ratio

7.34

Enterprise Value to Sales

15.76

Total Debt to Enterprise Value

0.01

Efficiency

Revenue/Employee

334,672.00

Income Per Employee

-175,660.00

Receivables Turnover

16.30

Total Asset Turnover

0.39

Liquidity

Current Ratio

5.36

Quick Ratio

5.29

Cash Ratio

5.00

Profitability

Gross Margin

25.57

Operating Margin

-53.59

Pretax Margin

-52.41

Net Margin

-52.49

Return on Assets

-20.53

Return on Equity

-27.37

Return on Total Capital

-26.79

Return on Invested Capital

-26.56

Capital Structure

Total Debt to Total Equity

5.64

Total Debt to Total Capital

5.33

Total Debt to Total Assets

4.49

Long-Term Debt to Equity

4.38

Long-Term Debt to Total Capital

4.15

Officers and Executives

Name Age Officer Since Title
Mr. John S. West 62 2011 President, Chief Executive Officer & Director
Mr. Aaron Tachibana 58 2019 Chief Financial Officer
Dr. Xavier Paliard - 2017 Vice President-Immunology, Research & Development
Dr. Richard O. Chen 48 2011 Chief Scientific Officer
Ms. Carol J. Tillis - 2011 Vice President-Finance & Administration

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
04/01/2021 Richard O. Chen
Chief Scientific Officer
12,517   Disposition at $25.69 per share. 321,561
04/01/2021 Richard O. Chen
Chief Scientific Officer
6,260   Disposition at $25.96 per share. 162,509
04/01/2021 Richard O. Chen
Chief Scientific Officer
21,223   Disposition at $25.61 per share. 543,521
04/01/2021 Richard O. Chen
Chief Scientific Officer
12,517   Derivative/Non-derivative trans. at $0.44 per share. 5,507
03/17/2021 Aaron Tachibana
Chief Financial Officer
2,446   Disposition at $26.73 per share. 65,381
03/17/2021 Richard O. Chen
Chief Scientific Officer
1,130   Disposition at $26.73 per share. 30,204
03/06/2021 Woodrow A. Myers
Director
2,610   Award at $0 per share. 0
03/02/2021 Aaron Tachibana
Chief Financial Officer
3,022   Disposition at $32.6 per share. 98,517
03/02/2021 Richard O. Chen
Chief Scientific Officer
345   Disposition at $32.6 per share. 11,247
02/01/2021 Richard O. Chen
Chief Scientific Officer
11,022   Disposition at $38.8 per share. 427,653
02/01/2021 Richard O. Chen
Chief Scientific Officer
2,400   Disposition at $38.12 per share. 91,488
02/01/2021 Richard O. Chen
Chief Scientific Officer
20,059   Disposition at $38.83 per share. 778,890
02/01/2021 Richard O. Chen
Chief Scientific Officer
6,519   Disposition at $38.19 per share. 248,960
02/01/2021 Richard O. Chen
Chief Scientific Officer
13,422   Derivative/Non-derivative trans. at $0.44 per share. 5,905
12/17/2020 Aaron Tachibana
Chief Financial Officer
2,391   Disposition at $36.37 per share. 86,960
12/17/2020 Richard O. Chen
Chief Scientific Officer
1,087   Disposition at $36.37 per share. 39,534
12/02/2020 Aaron Tachibana
Chief Financial Officer
2,926   Disposition at $27.76 per share. 81,225
12/02/2020 Richard O. Chen
Chief Scientific Officer
293   Disposition at $27.76 per share. 8,133
12/01/2020 Richard O. Chen
Chief Scientific Officer
25,612   Disposition at $28.14 per share. 720,721
12/01/2020 Richard O. Chen
Chief Scientific Officer
14,388   Disposition at $27.75 per share. 399,267
12/01/2020 Richard O. Chen
Chief Scientific Officer
40,000   Derivative/Non-derivative trans. at $0.44 per share. 17,600
10/20/2020 Abingworth LLP
130,486   Disposition at $27.66 per share. 3,609,242
10/19/2020 Abingworth LLP
196,423   Disposition at $27.86 per share. 5,472,344
/news/latest/company/us/psnl

MarketWatch News on PSNL

  1. Personalis upgraded to outperform from perform at Oppenheimer

    8:54 a.m. May 6, 2021

    - Tomi Kilgore

  2. Personalis stock price target cut to $37 from $50 at Truist

    9:30 a.m. March 1, 2021

    - Tomi Kilgore

  3. Personalis started at buy with $50 stock price target at Truist

    8:43 a.m. Jan. 28, 2021

    - Tomi Kilgore

  4. Personalis downgraded to perform from outperform at Oppenheimer

    9:01 a.m. Nov. 6, 2020

    - Tomi Kilgore

  5. 4 Biotech Stocks That Are Seeing Big Buys in June

    11:28 p.m. June 15, 2020

    - Barron's Online

  6. Personalis upgraded to buy from neutral at BofA Merrill Lynch

    10:03 a.m. Sept. 26, 2019

    - Tomi Kilgore

  7. Personalis started at outperform with $29 stock price target at Oppenheimer

    8:26 a.m. July 15, 2019

    - Tomi Kilgore

  8. Personalis sets IPO terms, which could value the genomics company at about $349.3 mln

    7:37 a.m. June 7, 2019

    - Tomi Kilgore

/news/nonmarketwatch/company/us/psnl

Other News on PSNL

  1. NKLA, ZNGA, HIMX and RUN among notable premarket gainers

    8:27 a.m. May 6, 2021

    - Seeking Alpha

  2. 10-Q: PERSONALIS, INC.

    4:30 p.m. May 5, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  3. Personalis inks deal with Mapkure for BGB-3245 development

    4:10 p.m. March 29, 2021

    - Seeking Alpha

  4. 10-K: PERSONALIS, INC.

    5:19 p.m. Feb. 25, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  5. What's in Store for Zomedica (ZOM)This Earnings Season?

    10:59 a.m. Feb. 12, 2021

    - Zacks.com

  6. Personalis: Still Going Strong

    3:50 a.m. Nov. 30, 2020

    - Seeking Alpha

  7. Loading more headlines...

At a Glance

Personalis, Inc.

1330 O'Brien Drive

Menlo Park, California 94025

Phone

1 6507521300

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$78.65M

Net Income

$-41.28M

2020 Sales Growth

20.6%

Employees

235.00

/news/pressrelease/company/us/psnl

Press Releases on PSNL

  1. Personalis Reports First Quarter 2021 Financial Results

    4:01 p.m. May 5, 2021

    - BusinessWire - BZX

  2. Personalis to Present at the 2021 Bank of America Healthcare Conference

    4:01 p.m. April 29, 2021

    - BusinessWire - BZX

  3. Personalis to Report First Quarter 2021 Financial Results on May 5, 2021

    4:01 p.m. April 21, 2021

    - BusinessWire - BZX

  4. Personalis Announces Changes to its Board of Directors

    6:00 p.m. March 8, 2021

    - BusinessWire - BZX

  5. Personalis Reports Fourth Quarter and Full Year 2020 Financial Results

    5:01 p.m. Feb. 25, 2021

    - BusinessWire - BZX

  6. Natera and Personalis Partner for Personalized Monitoring in Oncology

    10:01 a.m. Feb. 17, 2021

    - PR Newswire - PRF

  7. Natera and Personalis Partner for Personalized Monitoring in Oncology

    10:01 a.m. Feb. 17, 2021

    - BusinessWire - BZX

  8. Personalis to Present at Upcoming Investor Conferences

    5:01 p.m. Feb. 16, 2021

    - BusinessWire - BZX

  9. Personalis Announces Pricing of Public Offering of Common Stock

    11:09 p.m. Jan. 26, 2021

    - BusinessWire - BZX

  10. Personalis Announces Launch of Public Offering of Common Stock

    5:31 p.m. Jan. 26, 2021

    - BusinessWire - BZX

  11. Personalis Reports Preliminary Fourth Quarter 2020 Revenue

    5:01 p.m. Jan. 11, 2021

    - BusinessWire - BZX

  12. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.